Every biologic drug must be manufactured from a single cell clone — making clone selection one of the most consequential decisions in drug development.

Conventional workflows screen clones in 96-well plates, under conditions that bear little resemblance to a manufacturing bioreactor. The clone that looks best at small scale may fail at large scale — and by the time you find out, it's too late.

The result: costly late-stage failures, delayed regulatory filings, and drugs built on an incomplete picture.